Feasibility and efficacy of chemoradiotherapy with concurrent split-dose cisplatin after induction chemotherapy with docetaxel/cisplatin/5-fluorouracil for locally advanced head and neck cancer.
chemoradiotherapy
induction chemotherapy
locally advanced squamous cell carcinoma of the head and neck
nephrotoxicity
neurotoxicity
ototoxicity
split-dose concurrent high-dose cisplatin
Journal
Molecular and clinical oncology
ISSN: 2049-9450
Titre abrégé: Mol Clin Oncol
Pays: England
ID NLM: 101613422
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
received:
27
03
2020
accepted:
12
06
2020
entrez:
18
8
2020
pubmed:
18
8
2020
medline:
18
8
2020
Statut:
ppublish
Résumé
Chemoradiotherapy (CRT) with concurrent high-dose cisplatin (CDDP) is a standard treatment for locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN). Docetaxel plus CDDP and 5-fluorouracil (TPF) induction chemotherapy (ICT) prior to CRT is considered for patients at high risk of distant metastases. The purpose of the current study was to evaluate the feasibility and efficacy of CRT with split-dose CDDP after TPF-ICT for LA-SCCHN. A total of 21 LA-SCCHN patients treated with TPF-ICT followed by concurrent CRT with split-dose CDDP between January 2011 and December 2017 were retrospectively analysed. The patients' characteristics were i) median age 66 years (48-75 years); ii) male/female, 21/0; iii) performance status 0-1/2, 20/1; iv) larynx/hypopharynx/oropharynx/oral cavity, 4/8/8/1 and v) clinical stage III/IV, 3/18. The numbers of TPF-ICT cycles 1/2/3 were 2/3/16. Median cumulative doses of CDDP in TPF-ICT and CRT were 180.0 and 206.7 mg/m
Identifiants
pubmed: 32802331
doi: 10.3892/mco.2020.2105
pii: MCO-0-0-02105
pmc: PMC7412679
doi:
Types de publication
Journal Article
Langues
eng
Pagination
35Informations de copyright
Copyright © 2020, Spandidos Publications.
Références
Am J Physiol. 1996 Apr;270(4 Pt 2):F700-8
pubmed: 8967349
CA Cancer J Clin. 2013 Nov-Dec;63(6):419-37
pubmed: 24590861
N Engl J Med. 2007 Oct 25;357(17):1695-704
pubmed: 17960012
Radiother Oncol. 2012 Sep;104(3):300-4
pubmed: 22300609
Sci Rep. 2015 Jun 04;5:10798
pubmed: 26041604
J Clin Oncol. 2013 Aug 10;31(23):2854-60
pubmed: 23835714
N Engl J Med. 2003 Nov 27;349(22):2091-8
pubmed: 14645636
Radiother Oncol. 2016 Feb;118(2):238-43
pubmed: 26589131
Ann Oncol. 2018 May 1;29(5):1130-1140
pubmed: 29635316
J Biomed Sci. 2019 Mar 13;26(1):25
pubmed: 30866950
J Natl Cancer Inst. 2009 Dec 16;101(24):1682-95
pubmed: 19940282
Cancer. 1992 Jan 1;69(1):203-7
pubmed: 1309303
Lancet Oncol. 2013 Mar;14(3):257-64
pubmed: 23414589
J Clin Oncol. 2014 Dec 1;32(34):3858-66
pubmed: 25366680
N Engl J Med. 2007 Oct 25;357(17):1705-15
pubmed: 17960013
Head Neck. 2019 Feb;41(2):488-494
pubmed: 30536479
J Clin Oncol. 2013 Mar 1;31(7):853-9
pubmed: 23341517
J Neurol. 1992 Apr;239(4):199-204
pubmed: 1317914
Oncology. 2017;93(2):75-82
pubmed: 28511189
Eur J Cancer. 2002 Feb;38(3):387-91
pubmed: 11818204
Ann Oncol. 2014 Jan;25(1):216-25
pubmed: 24256848
Qual Life Res. 2006 Jun;15(5):791-800
pubmed: 16721639
J Clin Oncol. 2003 Jan 1;21(1):92-8
pubmed: 12506176
Biochem Pharmacol. 2001 Oct 15;62(8):1013-23
pubmed: 11597570
Oncology. 2013;85(6):364-9
pubmed: 24335484
Lancet. 2000 Mar 18;355(9208):949-55
pubmed: 10768432
Br J Cancer. 2001 Sep 14;85(6):823-6
pubmed: 11556831
Biomed Res Int. 2014;2014:967826
pubmed: 25165721
Radiother Oncol. 2009 Jul;92(1):4-14
pubmed: 19446902
Int J Clin Oncol. 2019 Jul;24(7):789-797
pubmed: 30796560
Head Neck. 2010 Feb;32(2):221-8
pubmed: 19557750